Agios Pharmaceuticals Inc IPO-Jahr
Was ist das IPO-Jahr von Agios Pharmaceuticals Inc?
IPO-Jahr von Agios Pharmaceuticals Inc ist 2013
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Agios Pharmaceuticals Inc
Was macht Agios Pharmaceuticals Inc?
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Unternehmen mit ipo-jahr ähnlich Agios Pharmaceuticals Inc
- AMG Capital Trust II hat IPO-Jahr von 2012
- Live Nation Entertainment hat IPO-Jahr von 2012
- MGM Resorts International hat IPO-Jahr von 2012
- EnerSpar hat IPO-Jahr von 2012
- The Western Union hat IPO-Jahr von 2012
- Wameja hat IPO-Jahr von 2012
- Agios Pharmaceuticals Inc hat IPO-Jahr von 2013
- Opus Bank hat IPO-Jahr von 2014
- Recro Pharma Inc hat IPO-Jahr von 2014
- Radius Recycling hat IPO-Jahr von 2014
- Progenity hat IPO-Jahr von 2014
- Axalta Coating Systems Ltd hat IPO-Jahr von 2014
- Anevia SA hat IPO-Jahr von 2014